Visionary Insights, Empowering the Future: Launch of the 2019 3rd Healthcare Investment Excellence Awards
The venture capital circle has never lacked classic investment cases that elicit acclaim, nor has it lacked discerning talent scouts.
On May 4, 2018, Ping An Good Doctor was listed on the Hong Kong Stock Exchange, marking the largest IPO in the Hong Kong stock market that year.
On December 24, 2018, Junshi Biosciences was listed on the Hong Kong Stock Exchange. Its first domestically developed and independently researched PD-1 monoclonal antibody, Tuoyi, was approved for market launch on December 17.
On February 26, 2019, CStone Pharmaceuticals, established just three years prior, went public in Hong Kong.
......
These are all listed companies from the previous annual Best Investment Cases of the VCBeat Healthcare Investment Excellence Awards.
As a professional ranking in the healthcare sector, the Zhuoyue List, from a third-party perspective, selects annual investment cases through real-name voting with “one vote per authoritative judge.” It creates an investment ranking list that combines subjective evaluations and objective data rankings in fields such as biopharmaceuticals, innovative medical devices, and healthcare services, truly possessing credibility and influence.
Behind every outstanding enterprise lies the indispensable boost of capital. The “Healthcare Investment Excellence Awards,” initiated and organized by Haoyue Capital, not only selects exceptional companies but also conducts a comprehensive review of objective metrics—including investment activity, deal volume, transaction value, and investment returns—for healthcare investment funds, based on publicly disclosed information and registration data submitted by various institutions, to identify the top investment funds of the year across different sectors.
Two editions of the “Best Investment Case” awards featured a total of 27 companies, with a combined valuation exceeding RMB 204.2 billion.
Of these, three have gone public, and seven unicorns have emerged.
With competitive innovative technologies and a profitable, closed-loop business model, many companies on the list have gradually emerged as leaders in their respective niche sectors. According to public estimates, the 27 listed companies have a combined valuation exceeding RMB 204.2 billion. Three of them went public shortly after being listed, all serving as leading enterprises in their specific segments. Beyond those that have already gone public, the other listed companies are also fiercely competing for market prominence.
As a unicorn enterprise in the biopharmaceutical sector, Henlius has won the Annual Biopharmaceutical Investment Case Award at the Zhuoyue List for two consecutive years. Since then, it has remained highly favored by investors, securing two rounds of financing in 2018 amounting to $190 million and $157 million, respectively, with its current valuation reaching RMB 20 billion. In December 2018, Henlius initiated its IPO process on the Hong Kong Stock Exchange. Its developed rituximab injection became the first biosimilar officially approved in China, marking a milestone in the biopharmaceutical industry.
As the first Chinese heart valve company to conduct global research, Venus Medtech possesses the first transcatheter heart valve system approved for market launch by the China Food and Drug Administration (CFDA), ushering in a new era in which China’s high-end innovative medical devices lead those in Europe and the United States. Following its listing in 2017, the company experienced rapid growth and reached a new investment agreement with All-Stars Capital in May 2018. Since the launch of the STAR Market, Venus Medtech has emerged as one of the companies poised to be among the first to list on this board.
The institutions listed in the 2nd “Best Investment Institutions” collectively manage over RMB 1.5 trillion in assets,
Dominating Half of the Venture Capital and Private Equity Landscape
Based on public data estimates, the investment institutions on the list manage over RMB 1.5 trillion in assets, with no shortage of those that have appeared on the list for two consecutive years.Sequoia Capital, Legend Capital, Qiming Venture Partners, Lilly Asia Ventures, Shenzhen Capital Group, Honghui Capital, Yuanhe OriginThese venture capital titans seemed entirely unaffected by the 2018 capital winter, a testament to their discerning investment acumen.
Legend Capital manages U.S. dollar and RMB funds with a total size exceeding RMB 40 billion. According to public information, it has invested in more than 70 companies in the healthcare sector, which accounts for the largest proportion of its portfolio and represents a key focus area for Legend Capital.
Qiming Venture Partners manages US dollar and RMB funds totaling nearly $4 billion and has invested in nearly 100 companies in the healthcare sector. It is the only investment firm whose portfolio companies have achieved listings or merger-related exits on major exchanges, including the New York Stock Exchange (NYSE), NASDAQ, Hong Kong Stock Exchange (HKEX), Taipei Exchange (TPEx), Shanghai Stock Exchange (SSE), and Shenzhen Stock Exchange (SZSE).
View More Past Zhuoyue List Editions with One Click:http://www.healthcarecapital.com.cn/zybd/index_13.aspx
The 3rd Zhuoyue List for Healthcare Investment is here as scheduled. It will select the Best Investment Firms and Best Investment Cases of 2018 from four hot sub-sectors in the current healthcare field: biopharmaceuticals, innovative medical devices, healthcare services, and new medical technologies.
The 3rd Healthcare & Medical Investment Zhuoyue List Summit, held in Pudong, Shanghai on April 10, 2019, will bring together 300+Professionals in the healthcare sector, including specialized healthcare investment funds, publicly listed companies, startups, research institutions, and industry mediaetc. Through roundtable discussions, keynote speeches, and multi-party dialogues, we explore innovative development models and commercialization strategies in four hot sectors: biopharmaceuticals, innovative medical devices, healthcare services, and new medical technologies.
The summit will feature the release of the thematic report “Breaking Through,” which synthesizes research insights from four specialized sectors and distills forward-looking perspectives for 2019. On the second day, a closed-door roadshow of innovative projects tailored for professional investors will be held, creating a premier summit experience that deciphers future investment trends in the healthcare and medical industry.
Scan the QR code or click the link now to register for the 2019 3rd Zhuoyue List Summit on Healthcare Investment.
